Search company, investor...

Qwell Pharmaceuticals

Founded Year

2008

Stage

Series A | Alive

Total Raised

$7M

Last Raised

$7M | 14 yrs ago

About Qwell Pharmaceuticals

Qwell Pharmaceuticals is a biotechnology company focused on small molecule development primarily for oncology indications.

Headquarters Location

1000 Second Avenue Suite 3700

Seattle, Washington, 98104,

United States

206-664-2516

Missing: Qwell Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Qwell Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Qwell Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Qwell Pharmaceuticals is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Qwell Pharmaceuticals Patents

Qwell Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/8/2016

12/10/2019

Skin care, Clusters of differentiation, Skin pigmentation, EC 3.4.24, Rare diseases

Grant

Application Date

3/8/2016

Grant Date

12/10/2019

Title

Related Topics

Skin care, Clusters of differentiation, Skin pigmentation, EC 3.4.24, Rare diseases

Status

Grant

Qwell Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Qwell Pharmaceuticals founded?

    Qwell Pharmaceuticals was founded in 2008.

  • Where is Qwell Pharmaceuticals's headquarters?

    Qwell Pharmaceuticals's headquarters is located at 1000 Second Avenue, Seattle.

  • What is Qwell Pharmaceuticals's latest funding round?

    Qwell Pharmaceuticals's latest funding round is Series A.

  • How much did Qwell Pharmaceuticals raise?

    Qwell Pharmaceuticals raised a total of $7M.

  • Who are the investors of Qwell Pharmaceuticals?

    Investors of Qwell Pharmaceuticals include ARCH Venture Partners and Wellcome Trust.

  • Who are Qwell Pharmaceuticals's competitors?

    Competitors of Qwell Pharmaceuticals include ChemoCentryx, Longevica, ADV Bioscience, Biosceptre International, Zymeworks and 13 more.

Compare Qwell Pharmaceuticals to Competitors

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

P
ParentPlus

ParentPlus LLC was formed to alleviate male-factor subfertility by bringing biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized perhaps in part because it frequently is neglected in the popular press. It is the company's belief that sperm from many subfertile men should be the target of a therapy based on modern biotechnology. Successful application of this concept could allow far more subfertile couples, when male-factor subfertility is a problem, to use IUI with spousal sperm to fulfill their dream of a having a baby. Hence, the focus of ParentPlus LLC is on reproductive media to enhance success primarily via IUI, but also enhancing IVF. In due course, demonstrated increased success rate with IUI using ParentPlus products will increase acceptance of IUI as the low cost alternative to highly publicized expensive treatments.

A
ADV Bioscience

ADV Bioscience is a biotechnology service company engaged in the application of self-developed, public domain technologies and licensed technologies primarily for gene discovery research and validation. The company's focus is offering these technologies primarily to the Chinese market.

Cizzle Biotechnology Logo
Cizzle Biotechnology

Cizzle Biotechnology Ltd are a biotechnology company developing gene-based strategies for the treatment and diagnosis of lung cancer.nCizzle Biotechnology Ltd is a spin-out company from the University of York, established in 2005 with support from the Bioscience Yorkshire Enterprise Fellowship program and funding from Yorkshire Forward.

A
Anaborex

Anaborex Anaborex is an early stage biotechnology company developing drugs for the treatment of the wasting syndrome many cancer patients experience towards the late stages of their disease.

P
Paratek Pharmaceuticals

Paratek is a biopharmaceutical company focused on the development, and commercialization of innovative antibiotics. Paratek's lead product candidate, omadacycline, is a novel tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Omadacycline has Special Protocol Assessment agreements with the U.S. Food and Drug Administration for the phase 3 trials planned in ABSSSI and CABP.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.